SCHEMBL24327378

SCHEMBL24327378

CN(C)C1CCN(c2ccc(N)c3c2OCO3)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
GAA P10253 3/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.35
HTT P42858 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAP4K4 O95819 1/20 0.33
PTPN11 Q06124 1/20 0.33
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
NR4A1 P22736 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661403 1.00 PDCD1 (0.37) PDCD1CD274GAAMEN1USP2
SCHEMBL24328516 0.91 PDCD1 (0.42) PDCD1CD274GAAMEN1USP2
SCHEMBL29661286 0.91 PDCD1 (0.42) PDCD1CD274GAAMEN1USP2
SCHEMBL29661420 0.78 CTSB (0.40) MEN1USP2KMT2AHTTALDH1A1
SCHEMBL24327320 0.78 CTSB (0.40) MEN1USP2KMT2AHTTALDH1A1
SCHEMBL24328563 0.77 PARP1 (0.40) PDCD1CD274GAAMEN1USP2
SCHEMBL29661326 0.77 PARP1 (0.40) PDCD1CD274GAAMEN1USP2
SCHEMBL29661397 0.76 TIPARP (0.34) PDCD1CD274GAAMEN1USP2
SCHEMBL24327498 0.76 TIPARP (0.34) PDCD1CD274GAAMEN1USP2
SCHEMBL15586058 0.73 ALDH1A1 (0.50) GAAMEN1USP2KMT2AL3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 PDCD1 293/4885CD274 1115/4885GAA 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.